BioGeometry
百奥几何
BioGeometry is a generative-AI company building next-generation tools for macromolecular drug discovery and bio-manufacturing, founded in 2021 by Jian Tang, then an associate professor at Mila, the Quebec AI Institute . The company emerged from Tang's early work in geometric deep learning and graph representation learning, with a stated long-term vision of developing programmable macromolecular drugs .
The company has raised at least two disclosed rounds: a $10-million angel round in September 2022 led by Gaorong Ventures, which also participated in a subsequent pre-A round in June 2024 alongside Jiangmen Ventures, Zhipu AI and Shengjing Jiacheng . Its flagship product is GeoFlow, a generative-AI protein design platform that Gaorong reported matched AlphaFold3's performance on antigen-antibody complex structure prediction as of September 2024 . Earlier, the team had open-sourced TorchProtein, a machine learning platform for macromolecular drug R&D developed jointly with NVIDIA, Intel and IBM .
BioGeometry has also pursued partnerships to commercialize its technology, including strategic collaborations with Yinjia Bio for protein and antibody drug co-development and with Alibaba Cloud for AI-powered bio-manufacturing solutions .
AI-generated — may contain errors, please verify.
Coverage
Elsewhere News | Neolix, LiblibAI, and others close landmark funding rounds, setting new industry records
"AI is the biggest variable in the future."
At the Intersection of Generative AI and Life Sciences: Technology Acceleration on One Side, Clinical Demand on the Other | Ronghui x NVIDIA Inception Program
NVIDIA, Gaorong Ventures, and Cornerstone Robotics on the Acceleration of "AI + Healthcare"
Rongbao | Generative AI Powers Industries, Snack Chains Hit 10,000 Stores, Chip Tape-Out Success, Healthcare Goes Global
Innovation lights the path to growth.
BioGeometry Completes Pre-A Round, Applying Generative AI to Bio-Manufacturing
Continuously optimizing a generative AI-powered protein design platform.
Accelerated R&D and Commercialization of Frontier Products: Medical Devices, Digital Services, and New Brands Go Global | Rongbao
As the year draws to a close and a new one begins, the pace never lets up.
The Golden Age of Large Models and Generative AI: Every Application Will Be Refreshed and Rewritten | Ronghui Visits Microsoft
Generative AI is driving industry-wide transformation.
BioGeometry's Jian Tang: How to Build a "ChatGPT" for Life Sciences | Gaorong Ventures
Generative AI is powering drug discovery.
Consumer/Medical Companies Launch New Products, Advanced Tech Market Share and Capacity Advance Further | Rongbao · November
Explore industry demand, and build solid R&D capabilities.
Energy storage batteries, chips, and other frontier sectors land funding; smart manufacturing leads the charge overseas | Rongbao · September
September milestone.
BioGeometry Closes Angel Round, Next-Generation AI to Power Macromolecular Drug R&D
Released TorchProtein, the first open-source machine learning platform for macromolecular drug discovery.
